Related Experiment Video
Updated: May 10, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Retropubic, laparoscopic, or robotic radical prostatectomy: is there any real difference?
Kelly A Healy1, Leonard G Gomella
1Department of Urology, Kimmel Cancer Center, Thomas Jefferson University Philadelphia, PA, USA.
Seminars in Oncology
|June 29, 2013
Summary
Robotic-assisted radical prostatectomy (RALP) is now the standard for localized prostate cancer, offering less blood loss and shorter hospital stays than open surgery (ORP). Long-term cancer control appears similar, but functional outcomes require further study.
Area of Science:
- Urology
- Surgical Oncology
Background:
- The surgical treatment for localized prostate cancer has significantly evolved over two decades.
- Open radical prostatectomy (ORP) was the traditional standard but has been largely superseded by robotic-assisted laparoscopic radical retropubic prostatectomy (RALP).
Purpose of the Study:
- To compare the outcomes of robotic-assisted laparoscopic radical retropubic prostatectomy (RALP) with open radical prostatectomy (ORP) for localized prostate cancer.
- To review the current literature regarding the efficacy and safety of different surgical approaches.
Main Methods:
- Review of current literature comparing ORP, RALP, and pure laparoscopic radical prostatectomy (LRP).
- Analysis of perioperative outcomes, including blood loss, hospital stay, cost, and functional results (impotence, incontinence).
Main Results:
- RALP is associated with reduced blood loss and shorter hospital stays compared to ORP, albeit at a higher cost.
- Oncologic outcomes appear comparable between RALP and ORP based on available data.
- Literature remains conflicted on functional outcomes like impotence and urinary incontinence, with limited long-term oncologic follow-up data.
Conclusions:
- RALP has become the predominant surgical approach for localized prostate cancer, offering perioperative benefits over ORP.
- Further high-quality, prospective studies with standardized reporting are needed to definitively compare functional outcomes and long-term oncologic control.
